Daily fluid intake and outcomes in kidney recipients: Post hoc analysis from the randomized ABCAN trial

M. Weber, D. Berglund, S. Reule, S. Jackson, A. J. Matas, H. N. Ibrahim

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Generous and even excessive fluid intake is routinely recommended to kidney transplant recipients despite minimal evidence to support this practice. We hypothesized that increased fluid intake, ascertained by 24-h urine volume output, may adversely affect graft outcomes as it would impose an extra workload on a limited number of nephrons. Kidney transplant recipients who were randomized to losartan vs. placebo in the Angiotensin II Blockade for Chronic Allograft Nephropathy (ABCAN) trial (n = 153) underwent baseline, five-yr biopsies, and annual iothalamate glomerular filtration rate assessment. Recipients with higher urine volume at randomization had higher urinary sodium and also higher urinary protein. The proportion using diuretics or CNI based regimens were similar across urinary volume tertiles. The highest urinary volume tertile (>2.56 L/d) did not predict the development of interstitial volume doubling or end-stage renal disease (ESRD) from interstitial fibrosis/tubular atrophy (OR = 3.52, 95% CI 0.4, 31.24, p = 0.26), interstitial volume doubling or all-cause ESRD (OR = 7.04, 95% CI 0.66, 74.87, p = 0.11), and was not associated with the conventional endpoint of doubling serum creatinine, all-cause ESRD, or death (OR = 0.89, 95% CI 0.21, 3.71, p = 0.87). These results suggest that the current practice of liberal fluid intake may not be beneficial in low risk and mostly Caucasian transplant recipients.

Original languageEnglish (US)
Pages (from-to)261-267
Number of pages7
JournalClinical Transplantation
Volume29
Issue number3
DOIs
StatePublished - Mar 1 2015

Keywords

  • Fluid intake
  • Graft failure
  • Kidney

Fingerprint Dive into the research topics of 'Daily fluid intake and outcomes in kidney recipients: Post hoc analysis from the randomized ABCAN trial'. Together they form a unique fingerprint.

Cite this